Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.
Thyrotropin-secreting pituitary adenomas are aggressive, invasive tumors that respond poorly to available surgical and medical treatments. Inappropriate release of thyrotropin by these tumors can result in hyperthyroidism. We treated five patients who had thyrotropin-secreting pituitary adenomas with the long-acting somatostatin analogue SMS 201-995, which was administered by subcutaneous injection in doses of 50 to 100 micrograms every 8 to 12 hours. Serum levels of thyrotropin were dramatically reduced by treatment in four of the five patients, and levels of another tumor marker, the alpha-subunit of thyrotropin, were reduced in all five. In two patients with hyperthyroidism due to production of excess thyrotropin by the tumor, treatment with the somatostatin analogue resulted in a sustained euthyroid state. One patient who was treated for more than 16 months had a persistent reduction in serum levels of thyrotropin and iodothyronines. We conclude that SMS 201-995 is an effective means of controlling hypersecretion of thyrotropin and the associated hyperthyroidism due to thyrotropin-secreting pituitary tumors.
D000236:Adenoma / Q000097:blood / Q000378:metabolism*; D000328:Adult; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000517:prevention & control; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D015282:Octreotide; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*
D013004:Somatostatin; D013972:Thyrotropin; D015282:Octreotide